Dual-vector prodrug activator gene therapy using retroviral replicating vectors

Shuji Kubo, Misato Takagi-Kimura, Masatoshi Tagawa, Noriyuki Kasahara

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Retroviral replicating vectors (RRVs) have been shown to achieve efficient tumor transduction and enhanced therapeutic benefits in a variety of cancer models. In the present study, we evaluated a possible combinatorial effect of prodrug activator genes delivered by two different RRVs derived from amphotropic murine leukemia virus (AMLV) and gibbon ape leukemia virus (GALV) on human hepatocellular carcinoma Hep3B cells. Both RRVs showed efficient replicative spread in culture and can overcame superinfection resistance each other. Notably, the replication and spread of each RRV in culture remained unaffected by pretransduction with the counterpart RRV. We further transduced cells with RRVs which individually possessed the prodrug activator genes yeast cytosine deaminase (CD) and herpes simplex virus thymidine kinase (TK) alone or in combination, and evaluated the cytotoxic effects of RRV-mediated gene therapy with CD and TK in the presence of the respective prodrugs, 5-fluorocytosine and ganciclovir. All combinations of the two prodrug activator genes produced synergistic cytocidal effects, but the combined effects of the different genes were significantly greater than those of the same genes when delivered by two different vectors. The present findings indicate the potential utility of dual-vector gene therapy using two different RRVs carrying different prodrug activator genes.

Original languageEnglish (US)
JournalCancer Gene Therapy
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Prodrugs
Genetic Therapy
Cytosine Deaminase
Genes
Thymidine Kinase
Gibbon ape leukemia virus
Flucytosine
Murine Leukemia Viruses
Superinfection
Ganciclovir
Simplexvirus
Hepatocellular Carcinoma
Neoplasms
Yeasts

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Cite this

Dual-vector prodrug activator gene therapy using retroviral replicating vectors. / Kubo, Shuji; Takagi-Kimura, Misato; Tagawa, Masatoshi; Kasahara, Noriyuki.

In: Cancer Gene Therapy, 01.01.2018.

Research output: Contribution to journalArticle

@article{63320ab19e2a4048b403ea9649462669,
title = "Dual-vector prodrug activator gene therapy using retroviral replicating vectors",
abstract = "Retroviral replicating vectors (RRVs) have been shown to achieve efficient tumor transduction and enhanced therapeutic benefits in a variety of cancer models. In the present study, we evaluated a possible combinatorial effect of prodrug activator genes delivered by two different RRVs derived from amphotropic murine leukemia virus (AMLV) and gibbon ape leukemia virus (GALV) on human hepatocellular carcinoma Hep3B cells. Both RRVs showed efficient replicative spread in culture and can overcame superinfection resistance each other. Notably, the replication and spread of each RRV in culture remained unaffected by pretransduction with the counterpart RRV. We further transduced cells with RRVs which individually possessed the prodrug activator genes yeast cytosine deaminase (CD) and herpes simplex virus thymidine kinase (TK) alone or in combination, and evaluated the cytotoxic effects of RRV-mediated gene therapy with CD and TK in the presence of the respective prodrugs, 5-fluorocytosine and ganciclovir. All combinations of the two prodrug activator genes produced synergistic cytocidal effects, but the combined effects of the different genes were significantly greater than those of the same genes when delivered by two different vectors. The present findings indicate the potential utility of dual-vector gene therapy using two different RRVs carrying different prodrug activator genes.",
author = "Shuji Kubo and Misato Takagi-Kimura and Masatoshi Tagawa and Noriyuki Kasahara",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/s41417-018-0051-0",
language = "English (US)",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Dual-vector prodrug activator gene therapy using retroviral replicating vectors

AU - Kubo, Shuji

AU - Takagi-Kimura, Misato

AU - Tagawa, Masatoshi

AU - Kasahara, Noriyuki

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Retroviral replicating vectors (RRVs) have been shown to achieve efficient tumor transduction and enhanced therapeutic benefits in a variety of cancer models. In the present study, we evaluated a possible combinatorial effect of prodrug activator genes delivered by two different RRVs derived from amphotropic murine leukemia virus (AMLV) and gibbon ape leukemia virus (GALV) on human hepatocellular carcinoma Hep3B cells. Both RRVs showed efficient replicative spread in culture and can overcame superinfection resistance each other. Notably, the replication and spread of each RRV in culture remained unaffected by pretransduction with the counterpart RRV. We further transduced cells with RRVs which individually possessed the prodrug activator genes yeast cytosine deaminase (CD) and herpes simplex virus thymidine kinase (TK) alone or in combination, and evaluated the cytotoxic effects of RRV-mediated gene therapy with CD and TK in the presence of the respective prodrugs, 5-fluorocytosine and ganciclovir. All combinations of the two prodrug activator genes produced synergistic cytocidal effects, but the combined effects of the different genes were significantly greater than those of the same genes when delivered by two different vectors. The present findings indicate the potential utility of dual-vector gene therapy using two different RRVs carrying different prodrug activator genes.

AB - Retroviral replicating vectors (RRVs) have been shown to achieve efficient tumor transduction and enhanced therapeutic benefits in a variety of cancer models. In the present study, we evaluated a possible combinatorial effect of prodrug activator genes delivered by two different RRVs derived from amphotropic murine leukemia virus (AMLV) and gibbon ape leukemia virus (GALV) on human hepatocellular carcinoma Hep3B cells. Both RRVs showed efficient replicative spread in culture and can overcame superinfection resistance each other. Notably, the replication and spread of each RRV in culture remained unaffected by pretransduction with the counterpart RRV. We further transduced cells with RRVs which individually possessed the prodrug activator genes yeast cytosine deaminase (CD) and herpes simplex virus thymidine kinase (TK) alone or in combination, and evaluated the cytotoxic effects of RRV-mediated gene therapy with CD and TK in the presence of the respective prodrugs, 5-fluorocytosine and ganciclovir. All combinations of the two prodrug activator genes produced synergistic cytocidal effects, but the combined effects of the different genes were significantly greater than those of the same genes when delivered by two different vectors. The present findings indicate the potential utility of dual-vector gene therapy using two different RRVs carrying different prodrug activator genes.

UR - http://www.scopus.com/inward/record.url?scp=85055552159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055552159&partnerID=8YFLogxK

U2 - 10.1038/s41417-018-0051-0

DO - 10.1038/s41417-018-0051-0

M3 - Article

C2 - 30348946

AN - SCOPUS:85055552159

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

ER -